← Back to Search

Monoclonal Antibodies

MEDI3506 for Diabetic Kidney Disease

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 29, day 85 and day 169

Summary

This trial is testing a new drug called MEDI3506 to help adults with diabetic kidney disease. The drug aims to reduce protein in the urine and improve kidney function. It is being tested on patients who may not fully respond to standard treatments.

Eligible Conditions
  • Diabetic Kidney Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 29, day 85 and day 169
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, day 29, day 85 and day 169 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population
Secondary study objectives
Asymptomatic Participants Tested Positive for COVID-19 During the Study - Safety Analysis Population
Immunogenicity of MEDI3506 - PK Analysis Population
Percent Change From Baseline to Day 169 (Week 24) in UACR - Full Analysis Population
+6 more
Other study objectives
Plasma Concentration of MEDI3506 - PK Analysis Population

Side effects data

From 2023 Phase 2 trial • 609 Patients • NCT04170543
6%
Hyperkalaemia
4%
Diarrhoea
4%
Urinary tract infection
3%
Covid-19
3%
Peripheral swelling
2%
Abdominal pain upper
2%
Constipation
2%
Pruritus
2%
Muscle spasms
2%
Nasopharyngitis
2%
Back pain
1%
Fungal skin infection
1%
Restless legs syndrome
1%
Pain in extremity
1%
Vomiting
1%
Cholecystitis acute
1%
Troponin increased
1%
Diverticulum intestinal
1%
Sleep apnoea syndrome
1%
Hypertension
1%
Hypovolaemia
1%
Pneumonia aspiration
1%
Renal impairment
1%
Musculoskeletal chest pain
1%
Orthopnoea
1%
Injection site inflammation
1%
Infected dermal cyst
1%
Asthenia
1%
Bile duct stone
1%
Brain natriuretic peptide increased
1%
Bleeding varicose vein
1%
Colitis microscopic
1%
C-reactive protein increased
1%
Hypervolaemia
1%
Type 2 diabetes mellitus
1%
Dyspnoea
1%
Oedema peripheral
1%
Hypokalaemia
1%
Gastritis erosive
1%
Toothache
1%
Pharyngitis
1%
Acute kidney injury
1%
Cellulitis
1%
Cardio-respiratory arrest
1%
Metabolic acidosis
1%
Foot deformity
1%
Faecaloma
1%
Vaccination complication
1%
Coronary artery disease
1%
Decreased appetite
1%
Drug hypersensitivity
1%
Gastric polyps
1%
Septic shock
1%
Weight increased
1%
Pancreatitis
1%
Head injury
1%
Hypothyroidism
1%
Cataract
1%
Hypernatraemia
1%
Vitamin d deficiency
1%
Muscle fatigue
1%
Fall
1%
Abdominal pain
1%
Cardiac failure
1%
Joint effusion
1%
Blood glucose increased
1%
Gastrooesophageal reflux disease
1%
Spinal stenosis
1%
Rash macular
1%
Intervertebral disc degeneration
1%
Folliculitis
1%
Dry skin
100%
80%
60%
40%
20%
0%
Study treatment Arm
MEDI3506 60 mg
MEDI3506 300 mg
MEDI3506 120 mg
MEDI3506 30 mg
Placebo

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 4Experimental Treatment2 Interventions
MEDI3506 Dose 4 plus Dapagliflozin (Day 85 to Day 168).
Group II: Group 3Experimental Treatment2 Interventions
MEDI3506 Dose 3 plus Dapagliflozin (Day 85 to Day 168).
Group III: Group 2Experimental Treatment2 Interventions
MEDI3506 Dose 2 plus Dapagliflozin (Day 85 to Day 168).
Group IV: Group 1Experimental Treatment2 Interventions
MEDI3506 Dose 1 plus Dapagliflozin (Day 85 to Day 168).
Group V: Group 5Placebo Group2 Interventions
Placebo (volume matched) plus Dapagliflozin (Day 85 to Day 168).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEDI3506
2021
Completed Phase 2
~1270
Dapagliflozin
2014
Completed Phase 4
~64440

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,397 Previous Clinical Trials
289,121,048 Total Patients Enrolled
~101 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top